CDK9 and prostate cancer: In line with these findings, our group found that the CDK9 inhibitor, CDKI-73, inhibits BRD4 activity and reprogrammed cancer-associated super-enhancers in prostate cancer cells, and that its combination with the BRD4 inhibitor AZD5153 was synergistic in patient-derived organoids and in vivo models [72].